Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Ltd ADR (NY: TAK )

13.56 +0.02 (+0.15%)
Official Closing Price Updated: 7:00 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules... 
Via Benzinga
Topics Climate Change
Exposures Climate
Preview: Takeda Pharmaceutical's Earnings
Via Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... 
Via Benzinga
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
Exposures Product Safety
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... 
Via Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... 
Via Benzinga
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... 
Via Talk Markets
Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report
Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020. 
Via Benzinga
Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600
Protagonist Therapeutics will join the SmallCap 600 on Wednesday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail?
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. 
Via Benzinga
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet and Lennox-Gastaut syndromes 
Via Benzinga
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi... 
Via Talk Markets
7 F-Rated Stocks to Avoid at All Costs in June
The stock market is doing well this year, so it would be a tragedy to own F-rated stocks. Here are some key stocks to avoid in June. 
Via InvestorPlace
Blackstone Weighs Sale Of Japanese Pharma Firm Alinamin: Report
Blackstone reportedly considers sale of Japanese consumer healthcare firm Alinamin Pharmaceutical (previously owned by Takeda) for $1.9B, attracting interest from other firms. 
Via Benzinga
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
Week in Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
In the headline deal, Takeda acquires global rights from AC Immune of Switzerland for $100 million upfront and up to $2.1B in milestones. 
Via Talk Markets
Takeda's Dengue Vaccine Gets WHO Approval, Eligible for UN Procurement
Takeda's dengue vaccine, Qdenga, gains WHO prequalification, enabling UN agency procurement. Approved in multiple countries, Qdenga is recommended for children 6-16 in high dengue areas. 
Via Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Unlocking hope for Alzheimer's with ACI-24.060. Takeda's agreement with AC Immune targets toxic forms of Abeta, potentially slowing disease progression. 
Via Benzinga
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical. 
Via InvestorPlace
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.